Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$5.09 USD

5.09
264,873

-0.19 (-3.60%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $5.07 -0.02 (-0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

by Zacks Equity Research

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

by Zacks Equity Research

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

Innate Pharma's Filing for Leukemia Drug Accepted in Europe

by Zacks Equity Research

The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.

Pulmatrix Surges on License Agreement With Johnson & Johnson

by Zacks Equity Research

Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.

Amicus Progresses on Pipeline Development Amid Competition

by Zacks Equity Research

Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.

Arena (ARNA) Expands Strategic Deal With Beacon Discovery

by Zacks Equity Research

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

All You Need to Know About Agenus (AGEN) Rating Upgrade to Buy

by Zacks Equity Research

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agenus (AGEN) Up 24.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

Moving Average Crossover Alert: Agenus

by Zacks Equity Research

Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss

by Zacks Equity Research

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.

Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat

by Zacks Equity Research

Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Will Agenus Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Agenus.

Are You Looking for a Top Momentum Pick? Why Agenus (AGEN) is a Great Choice

by Zacks Equity Research

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 13.16% and 27.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?

by Zacks Equity Research

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

by Zacks Equity Research

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs

by Zacks Equity Research

Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.

Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?

by Zacks Equity Research

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.